115195
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
NLRP3 炎症小体激活对冠心病不稳定斑块和主要不良心血管事件的预测价值
Authors Liu Y, Guo X, Pan J, Jin J, Li J , Hou Y, Wang M, Bai J, Fan Y
Received 10 July 2025
Accepted for publication 28 December 2025
Published 13 January 2026 Volume 2026:19 550023
DOI https://doi.org/10.2147/JIR.S550023
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Rongxue Wu
Yaping Liu,1 Xiangqian Guo,1 Jiping Pan,1 Jianjian Jin,2 Jing Li,2 Yanjun Hou,3 Mingzhen Wang,3 Jianhua Bai,3 Yan Fan2
1The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, 730000, People’s Republic of China; 2Department of Cardiology, Gansu Provincial Hospital, Lanzhou, 730000, People’s Republic of China; 3Department of Cardiology, Dongxiang County Hospital, Linxia, 731400, People’s Republic of China
Correspondence: Yan Fan, Email 441429048@qq.com
Background: The role of Nod-like receptor protein 3 (NLRP3) inflammasome activation in unstable plaques remains incompletely elucidated. This study aimed to investigate whether the NLRP3 inflammasome and its downstream cytokine IL-1β serve as predictors of unstable plaques and subsequent major adverse cardiovascular events (MACE) in patients with coronary heart disease (CHD).
Methods: The study enrolled 232 patients diagnosed with CHD at Gansu Provincial Hospital between May 2023 and June 2024. Based on standardized plaque vulnerability criteria assessed by intravascular ultrasound (IVUS) or optical coherence tomography (OCT), patients were divided into a stable plaque group (n=143) and an unstable plaque group (n=89). Serum concentrations of NLRP3 and IL-1β were measured using ELISA. During a median follow-up of 14 months (IQR, 7– 20), the primary composite endpoint was MACE, defined as recurrent myocardial infarction, rehospitalization due to heart failure, or all-cause death.
Results: NLRP3 and IL-1β were identified as independent predictors of unstable plaques in CHD (OR=1.002 and 1.030, respectively), demonstrating high predictive value for plaque rupture and erosion (AUCs: 0.817 and 0.727 for rupture; 0.760 and 0.758 for erosion). Furthermore, elevated levels of these biomarkers were independently associated with an increased risk of MACE (HR=1.006 for NLRP3; HR=1.056 for IL-1β). Kaplan-Meier analysis confirmed that patients with high biomarker levels experienced a significantly higher incidence of MACE (log-rank P < 0.001). The high predictive accuracy of both biomarkers for MACE was further substantiated by AUC values of 0.874 (NLRP3) and 0.870 (IL-1β).
Conclusion: NLRP3 inflammasome activation is a key predictor of unstable plaques (including rupture and erosion) and subsequent MACE in CHD patients, highlighting its strong promise as a clinical biomarker for refining risk stratification and guiding future therapies.
Keywords: coronary heart disease, unstable plaques, NLRP3 inflammasome, IL-1β, major adverse cardiovascular events
1The First School of Clinical Medical, Gansu University of Chinese Medicine, Lanzhou, 730000, People’s Republic of China; 2Department of Cardiology, Gansu Provincial Hospital, Lanzhou, 730000, People’s Republic of China; 3Department of Cardiology, Dongxiang County Hospital, Linxia, 731400, People’s Republic of China
Correspondence: Yan Fan, Email 441429048@qq.com
Background: The role of Nod-like receptor protein 3 (NLRP3) inflammasome activation in unstable plaques remains incompletely elucidated. This study aimed to investigate whether the NLRP3 inflammasome and its downstream cytokine IL-1β serve as predictors of unstable plaques and subsequent major adverse cardiovascular events (MACE) in patients with coronary heart disease (CHD).
Methods: The study enrolled 232 patients diagnosed with CHD at Gansu Provincial Hospital between May 2023 and June 2024. Based on standardized plaque vulnerability criteria assessed by intravascular ultrasound (IVUS) or optical coherence tomography (OCT), patients were divided into a stable plaque group (n=143) and an unstable plaque group (n=89). Serum concentrations of NLRP3 and IL-1β were measured using ELISA. During a median follow-up of 14 months (IQR, 7– 20), the primary composite endpoint was MACE, defined as recurrent myocardial infarction, rehospitalization due to heart failure, or all-cause death.
Results: NLRP3 and IL-1β were identified as independent predictors of unstable plaques in CHD (OR=1.002 and 1.030, respectively), demonstrating high predictive value for plaque rupture and erosion (AUCs: 0.817 and 0.727 for rupture; 0.760 and 0.758 for erosion). Furthermore, elevated levels of these biomarkers were independently associated with an increased risk of MACE (HR=1.006 for NLRP3; HR=1.056 for IL-1β). Kaplan-Meier analysis confirmed that patients with high biomarker levels experienced a significantly higher incidence of MACE (log-rank P < 0.001). The high predictive accuracy of both biomarkers for MACE was further substantiated by AUC values of 0.874 (NLRP3) and 0.870 (IL-1β).
Conclusion: NLRP3 inflammasome activation is a key predictor of unstable plaques (including rupture and erosion) and subsequent MACE in CHD patients, highlighting its strong promise as a clinical biomarker for refining risk stratification and guiding future therapies.
Keywords: coronary heart disease, unstable plaques, NLRP3 inflammasome, IL-1β, major adverse cardiovascular events